LSI USA

Paul LaViolette of SV Health Investors and moderator Ilya Trakhtenberg from L.E.K. Consulting discuss essential strategies and best practices innovators must adopt to successfully navigate and win in the medtech industry. For more information watch this video https://www.lifesciencemarketresearch.com/videos/the-best-practices-every-innovator-needs-to-win-in-medtech-lsi-usa-25  

To successfully navigate these differences, panelists emphasized the need for clear communication—especially early in the partnership. “Founders often assume everyone’s aligned just because they invested,” said Mas. “But if expectations haven’t been discussed, you end up with drama in the boardroom.” When it comes to big tech and big pharma partnerships, misalignment is even more likely. “I’ve seen firsthand how tech and pharma bring very different assumptions to the table,” said Parramon. “Pharma thinks software guys can fix everything. Tech guys don’t think about evidence at all. If you haven’t aligned on the how—not just the goal—it will fall apart.” Doctor emphasized that data is now a vital currency in medtech, especially with AI on the rise. “Many investors won’t look at you without a data strategy. However, healthcare is fragmented. Getting external data is a nightmare, so the data you collect from your own product becomes incredibly valuable.” He advised companies to treat data...

  Industry experts Howard Levin (Gelixir Healthcare), Lisa Carmel (Medtech Women), Karun Naga (The Foundry), and moderator Jie Wang discuss emerging trends, innovations, and future directions in renal denervation technology. For more information watch this video:  https://www.youtube.com/watch?v=Fsj5ycxHmQE&t=152s

Central to Ali’s perspective is the necessity of diverse data. “Most of the machine learning models were based on 65-year-old white males,” he explained. “So the previous data may not represent the cohort that you’re trying to apply these models to.” This imbalance extends to data management and integration. “There’s death by data,” Ali said. “Accurate data is key. MD doesn’t just mean medical doctor; it means make decisions.”Ali called for agnostic, interoperable dashboards that integrate with existing EMRs. Without this, providers face a flood of data with little guidance on clinical relevance. For more information visit here:  https://www.sharepresentation.com/LSIUSA26/imperative-cardiac-wearables-inclusivity-interoperability-insight  

Artificial intelligence continues to gain ground across healthcare, but no specialty appears more ready, or more in need, of transformation than cardiovascular care. From improving diagnostics to enabling automation,  AI in cardiovascular imaging  is creating new possibilities for how providers detect, monitor, and intervene in heart disease. At LSI USA ’25, industry leaders from GE HealthCare, CorVista Health, Vista.ai, and Recode Ventures explored why cardiovascular medicine has become a proving ground for AI’s most advanced use cases, and what’s next. Why Cardiology Leads the AI Curve “Cardiology is rich with data: structured, multimodal data. Many problems in this field lend themselves well to automation and pattern recognition,” said Gera, who leads Cardiovascular and Interventional solutions at GE HealthCare. “It’s not just about workflow or clinical decision support. AI can elevate itself across the care continuum, from screening to diagnostics to intervention, all the ...

As technologies evolve and  healthcare innovation  accelerates, the traditional boundaries separating medtech, big tech, and big pharma are increasingly blurry — but the cultural and strategic gaps between them remain. At LSI USA ’25, panelists Juan-Pablo Mas (Action Potential Venture Capital), Nishant Doctor (Surf Therapeutics), and Jordi Parramon (Nexus NeuroTech Ventures) joined moderator Katie Elias to examine how medtech can better align with  big tech and big pharma  to drive innovation forward. The conversation centered on key differences in development strategy, investor expectations, and business timelines — critical challenges that arise when building partnerships or raising capital across sectors. As medtech companies seek broader platforms and more ambitious outcomes, understanding and navigating these differences becomes essential for effective cross-sector collaboration and long-term success. Understanding the Evidence Gap A major area of divergence bet...

For years, medical robotics has been synonymous with high-cost, high-precision interventions — think large surgical robots in complex operating rooms. But a new generation of robotics companies is upending that paradigm by targeting more routine, high-volume procedures that strain provider bandwidth and expose systemic inefficiencies. At LSI USA ’25, a panel of operator-led companies took the stage to discuss how their technologies are addressing two of the biggest challenges in healthcare: provider scarcity and rising costs. While traditional robotics may have focused on elite surgical tasks, the next wave is all about scalable, task-specific solutions that work within real-world clinical and economic constraints. From Specialized to Scalable: Redefining the Role of Medical Robotics Rather than targeting a handful of high-reimbursement procedures, these companies are applying robotics to common clinical workflows —  vascular access , phlebotomy, biopsies — that collectively accoun...